5-HTTLPR-rs25531 and Antidepressant Treatment Outcomes in Korean Patients with Major Depression

Abstract

Introduction Despite the ethnic differences in 5-HTTLPR (S allele relates to better antidepressant response in Korean and Japanese people, while L allele with better response in Caucasians), it is unclear whether 5-HTTLPR and its high expression locus rs25531 are interactively associated with antidepressant treatment outcome. We investigated the individual and interaction effects of these polymorphisms on antidepressant treatment outcomes in the Korean population.

Methods A total of 464 Korean subjects with major depressive disorder completed 6 weeks of antidepressant monotherapy. Venous blood was extracted for genotyping 5-HTTLPR and rs25531 by polymerase chain reaction and DNA sequencing. We used logistic regression analyses to verify the main and interaction effects of 5-HTTLPR and rs25531 on response and remission after antidepressant treatment.

Results After adjusting for covariates, the SS genotype of 5-HTTLPR was significantly associated with better treatment outcomes (p<0.001, odds ratio [OR] [95% confidence interval (CI)]=2.435 [1.551, 3.823] in response; p<0.001, OR [95% CI]=2.912 [1.730, 4.903] in remission), while G-containing genotype (AG+GG) of rs25531 was only associated with remission (p=0.034, OR [95% CI]=2.104 [1.058, 4.181]). The interaction effect of 5-HTTLPR and rs25531 on response and remission was insignificant (all p>0.05).

Discussion Our findings suggest variations in allelic frequency and functionality of 5-HTTLPR and rs25531 among the different ethnicities. We found a minor advantage of rs25531 in achieving remission. However, there was no interaction effect with 5-HTTLPR.

Key words

antidepressant treatment outcome - depression - 5-HTTLPR - rs25531 - Korean

• References

• 1 Licinio J, Wong ML. Pharmacogenomics of antidepressants: what is next?. Mol Psychiatry 2010; 15: 445
• 2 Smeraldi E, Zanardi R, Benedetti F. et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511
• 3 Kim DK, Lim SW, Lee S. et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219
• 4 Ren F, Ma Y, Zhu X. et al. Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder. J Affect Disord 2020; 273: 254-264
• 5 Gressier F, Bouaziz E, Verstuyft C. et al. 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr Genet 2009; 19: 195-200
• 6 Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500
• 7 Myung W, Lim SW, Kim S. et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berl) 2013; 225: 283-290
• 8 Kim H, Lim SW, Kim S. et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006; 296: 1609-1618
• 9 Goldman N, Glei DA, Lin YH. et al. The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depress Anxiety 2010; 27: 260-269
• 10 Odgerel Z, Talati A, Hamilton SP. et al. Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health’s Collaborative Center for Genomic Studies. Transl Psychiatry 2013; 3: e307
• 11 Kunugi H, Hattori M, Kato T. et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997; 2: 457-462
• 12 Iurescia S, Seripa D, Rinaldi M. Role of the 5-HTTLPR and SNP promoter polymorphisms on serotonin transporter gene expression: a closer look at genetic architecture and in vitro functional studies of common and uncommon allelic variants. Mol Neurobiol 2016; 53: 5510-5526
• 13 Mrazek DA, Rush AJ, Biernacka JM. et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009; 150b: 341-351
• 14 Gudayol-Ferré E, Herrera-Guzmán I, Camarena B. et al. Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms. Hum Psychopharmacol 2012; 27: 577-586
• 15 Julia S, Stefan L, Barbara L. et al. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genetic Testing and Molecular. Biomarkers 2014; 18: 20-31
• 16 Hu XZ, Rush AJ, Charney D. et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64: 783-792
• 17 Kraft JB, Peters EJ, Slager SL. et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007; 61: 734-742
• 18 Reimherr F, Amsterdam J, Dunner D. et al. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. Psychiatry Res 2010; 175: 67-73
• 19 First MB, Gibbon M. The structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured clinical interview for DSM-IV axis II disorders (SCID-II). In: Hilsenroth MJ, Segal DL, eds. Comprehensive Handbook of Psychological Assessment, Volume 2: Personality Assessment. Hoboken, NJ: John Wiley & Sons Inc; 2004: 134–143
• 20 Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296
• 21 Nonen S, Kato M, Takekita Y. et al. Polymorphism of rs3813034 in serotonin transporter gene SLC6A4 is associated with the selective serotonin and serotonin-norepinephrine reuptake inhibitor response in depressive disorder: sequencing analysis of: SLC6A4. J Clin Psychopharmacol 2016; 36: 27-31
• 22 Karasu TB, Gelenberg A, Wang P. et al. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157: 1-45
• 23 Lingjærde O, Ahlfors UG, Bech P. et al. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987; 76: 100-100
• 24 Minelli C, Thompson JR, Abrams KR. et al. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 2005; 34: 1319-1328
• 25 Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 1998; 63: 1531-1540
• 26 Wittke-Thompson JK, Pluzhnikov A, Cox NJ. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 967-986
• 27 Maron E, Tammiste A, Kallassalu K. et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 2009; 19: 451-456
• 28 Bonvicini C, Minelli A, Scassellati C. et al. Serotonin transporter gene polymorphisms and treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 934-939
• 29 Watanabe SY, Iga J, Numata S. et al. Polymorphism in the promoter of the gene for the serotonin transporter affects the age of onset of major depressive disorder in the Japanese population. J Affect Disord 2015; 183: 156-158
• 30 Li YR, Keating BJ. Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations. Genome Med 2014; 6: 91-104
• 31 Yamazaki K, Yoshino Y, Mori T. et al. Association study and meta-analysis of polymorphisms, methylation profiles, and peripheral mRNA expression of the serotonin transporter gene in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2016; 41: 334-347
• 32 Iga J, Watanabe SY, Numata S. et al. Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder. Hum Psychopharmacol 2016; 31: 193-199
• 33 Lo SK, Li IT, Tsou TS. et al. [Non-significant in univariate but significant in multivariate analysis: a discussion with examples]. Changgeng Yi Xue Za Zhi 1995; 18: 95-101
• 34 Iglesias C, Alonso M. Residual symptoms in depression. Actas Esp Psiquiatr 2009; 37: 101-105
• 35 Gudayol-Ferré E, Guàrdia-Olmos J, Peró-Cebollero M. et al. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables. J Affect Disord 2013; 150: 1082-1090
• 36 Kao WT, Chang CL, Lung FW. 5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial. J Affect Disord 2018; 238: 597-608
• 37 Kato M, Nonen S, Serretti A. et al. 5-HTTLPR rs25531A>G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. J Clin Psychopharmacol 2013; 33: 131-132
• 38 Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006; 367: 153-167
• 39 Trivedi MH, Rush AJ, Wisniewski SR. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
• 40 Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013; 170: 723-733
• 41 Bosman RC, Waumans RC, Jacobs GE. et al. Failure to respond after reinstatement of antidepressant medication: A systematic review. Psychother Psychosom 2018; 87: 268-275
• 42 Durham LK, Webb SM, Milos PM. et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004; 174: 525-529